Our latest news, announcements and resources
News Releases
October 1, 2026
MSD Animal Health Highlights Landmark Clinical Research on Gilvetmab, the First Caninized Immune Checkpoint Inhibitor for Canine Oncology in the Journal of Veterinary Internal Medicine and Journal of the American Veterinary Medical Association
MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) has granted a conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution). This innovative product is in the newest class of parasiticides known as isoxazolines.
September 29, 2026
MSD Animal Health Showcases New Research Advancing Ruminant Health at World Buiatrics Congress
MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), presented more than 50 new studies at the 33rd World Buiatrics Congress in Istanbul, Turkey.
August 24, 2026
Mexico’s SADER Approves MSD Animal Health’s BRAVECTO® (Fluralaner) Chew Tableta Masticable (Chew) for the Treatment of New World Screwworm (Cochliomyia hominivorax) in Dogs
MSD Animal Health, a division of MSD & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced Mexico’s SADER granted approval for BRAVECTO® (Fluralaner) Chew Tableta Masticable (Chew) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis).
July 31, 2026
European Commission Grants Marketing Authorization for NOBIVAC NXT HCPChFeLV from MSD Animal Health
MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) has granted a conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution). This innovative product is in the newest class of parasiticides known as isoxazolines.
July 20, 2026
Study from MSD Animal Health Reveals Opportunity to Increase Feline Vaccination through Knowledge Sharing Between Veterinarians and Cat Owners
MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the publication of results from a recent global survey of cat owners and veterinarians aimed at uncovering key drivers, barriers and unmet needs affecting feline vaccination compliance. The study, “Drivers, Barriers, and Unmet Needs affecting Feline Vaccination Compliance: Insights from a Global Survey of Cat Owners and Veterinarians,” was presented at the 2026 World Feline Congress 2026 June 26-28, 2026 and published in the journal Veterinary Sciences.
June 17, 2026
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) has granted a conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution). This innovative product is in the newest class of parasiticides known as isoxazolines.
Featured Stories
Next-Gen Calf Care: SenseHub® Dairy Youngstock Now Available for Bucket-Fed Calves
Following rigorous internal validation and successful commercial farm trials, MSD Animal Health has expanded the capabilities of its SenseHub® Dairy Youngstock monitoring solution to now include monitoring of bucket-fed calves.
Thirty years of the Afya Program: The science and innovation driving global rabies elimination
As we celebrate 30 years of the Afya Program, MSD Animal Health remains committed to using scientific innovation and community partnerships to ensure that life-saving access reaches the communities that need it most.
New Global Survey Shows Itch is Taking a Toll on Pets, Owners and Vets
A new global survey, “Pet Owner and Vet Perspectives on Canine Pruritus,” reveals that itchy skin and allergic skin disease are among the most common reasons dogs visit the veterinarian. About one in three canine patients in the U.S. (and more than one in four worldwide) are seen for itchy skin or allergic skin disease, and about two in five dogs with skin conditions are newly diagnosed. The impact extends well beyond the dog: 34% of U.S. dog owners (31% globally) say their dog’s allergic skin disease significantly affects their own quality of life, and 61% of U.S. owners (60% globally) have booked vet appointments specifically for their dog’s itchy skin.
‘Hidden’ Parasitic Infections in Dairy Cattle Cost the Industry Billions Every Year
Recent research suggests that the global impact of parasites is far greater than many realize, costing the industry billions of dollars each year, with most losses driven by reduced performance.
Saving the Herds of Lapland: How an Antiparasitic Drug Helped Preserve Reindeer, Livelihoods, and Culture
In the early 1970s, reindeer herds across Lapland were in crisis. Parasitic infections were decimating calves, with losses in some herds reaching as high as sixty percent.
Protecting Tilapia Production: Field Evidence that Vaccination Saves Fish and Stabilizes Yields
Streptococcosis and a viral disease known as infectious spleen and kidney necrosis (ISKNV) are two of the most consequential infectious threats to tilapia farmers worldwide.
MSD Animal Health Media Center
Explore our library of assets such as logos, company descriptions and key photos, all intended for use by media professionals.